Diamyd Medical AB (publ) - Asset Resilience Ratio

Latest as of November 2025: 77.10%

Diamyd Medical AB (publ) (DMYD-B) has an Asset Resilience Ratio of 77.10% as of November 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Diamyd Medical AB (publ) (DMYD-B) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

Skr233.19 Million

≈ $25.09 Million USD Cash + Short-term Investments

Total Assets

Skr302.46 Million

≈ $32.55 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2011–2025)

This chart shows how Diamyd Medical AB (publ)'s Asset Resilience Ratio has changed over time. See Diamyd Medical AB (publ) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Diamyd Medical AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Diamyd Medical AB (publ).

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr213.33 Million	70.53%
Short-term Investments	Skr19.85 Million	6.56%
Total Liquid Assets	Skr233.19 Million	77.10%

Asset Resilience Insights

Very High Liquidity: Diamyd Medical AB (publ) maintains exceptional liquid asset reserves at 77.10% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Diamyd Medical AB (publ) Industry Peers by Asset Resilience Ratio

Compare Diamyd Medical AB (publ)'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Argen-X F:1AE	Biotechnology	25.67%
Tubize-Fin BR:TUB	Biotechnology	0.05%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
Dashenlin Pharm Grp Co Ltd SHG:603233	Biotechnology	0.02%
Staidson Beijing Biopharma SHE:300204	Biotechnology	7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	41.25%
Ardelyx Inc NASDAQ:ARDX	Biotechnology	41.14%
Xiangxue Pharmaceutical SHE:300147	Biotechnology	0.05%

Annual Asset Resilience Ratio for Diamyd Medical AB (publ) (2011–2025)

The table below shows the annual Asset Resilience Ratio data for Diamyd Medical AB (publ).

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-08-31	78.60%	Skr277.19 Million ≈ $29.83 Million	Skr352.64 Million ≈ $37.95 Million	+17.62pp
2024-08-31	60.99%	Skr132.37 Million ≈ $14.24 Million	Skr217.04 Million ≈ $23.36 Million	-0.70pp
2023-08-31	61.69%	Skr126.96 Million ≈ $13.66 Million	Skr205.81 Million ≈ $22.15 Million	-5.82pp
2022-08-31	67.51%	Skr159.67 Million ≈ $17.18 Million	Skr236.52 Million ≈ $25.45 Million	-1.68pp
2021-08-31	69.19%	Skr139.38 Million ≈ $15.00 Million	Skr201.44 Million ≈ $21.68 Million	-6.97pp
2020-08-31	76.16%	Skr68.36 Million ≈ $7.36 Million	Skr89.76 Million ≈ $9.66 Million	-0.27pp
2019-08-31	76.43%	Skr56.71 Million ≈ $6.10 Million	Skr74.20 Million ≈ $7.99 Million	-3.80pp
2018-08-31	80.23%	Skr44.11 Million ≈ $4.75 Million	Skr54.98 Million ≈ $5.92 Million	-6.67pp
2017-08-31	86.90%	Skr85.72 Million ≈ $9.23 Million	Skr98.65 Million ≈ $10.62 Million	+3.79pp
2016-08-31	83.11%	Skr31.40 Million ≈ $3.38 Million	Skr37.78 Million ≈ $4.07 Million	+55.24pp
2015-08-31	27.87%	Skr13.00 Million ≈ $1.40 Million	Skr46.65 Million ≈ $5.02 Million	+6.39pp
2014-08-31	21.48%	Skr10.96 Million ≈ $1.18 Million	Skr51.02 Million ≈ $5.49 Million	-29.70pp
2012-08-31	51.18%	Skr215.85 Million ≈ $23.23 Million	Skr421.74 Million ≈ $45.39 Million	-2.29pp
2011-08-31	53.48%	Skr277.86 Million ≈ $29.90 Million	Skr519.60 Million ≈ $55.92 Million	--

pp = percentage points

About Diamyd Medical AB (publ)

ST:DMYD-B Sweden Biotechnology

Market Cap

$15.63 Million

Skr145.25 Million SEK

Market Cap Rank

#25734 Global

#535 in Sweden

Share Price

Skr1.08

Change (1 day)

+2.85%

52-Week Range

Skr1.02 - Skr17.62

All Time High

Skr71.00